TEMPEST THERAPEUTICS INC (TPST)

US87978U1088 - Common Stock

0.9492  0 (-0.28%)

After market: 0.9599 +0.01 (+1.13%)

Fundamental Rating

2

TPST gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. While TPST seems to be doing ok healthwise, there are quite some concerns on its profitability. TPST is valued expensive and it does not seem to be growing.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TPST has reported negative net income.
TPST had a negative operating cash flow in the past year.
TPST had negative earnings in each of the past 5 years.
In the past 5 years TPST always reported negative operating cash flow.

1.2 Ratios

TPST has a worse Return On Assets (-104.97%) than 77.48% of its industry peers.
TPST's Return On Equity of -310.01% is on the low side compared to the rest of the industry. TPST is outperformed by 75.50% of its industry peers.
Industry RankSector Rank
ROA -104.97%
ROE -310.01%
ROIC N/A
ROA(3y)-57.76%
ROA(5y)-63.32%
ROE(3y)-128.62%
ROE(5y)-114.41%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TPST does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, TPST has more shares outstanding
TPST has more shares outstanding than it did 5 years ago.
TPST has a better debt/assets ratio than last year.

2.2 Solvency

TPST has an Altman-Z score of -10.02. This is a bad value and indicates that TPST is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TPST (-10.02) is worse than 74.41% of its industry peers.
There is no outstanding debt for TPST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.02
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

TPST has a Current Ratio of 1.69. This is a normal value and indicates that TPST is financially healthy and should not expect problems in meeting its short term obligations.
TPST's Current ratio of 1.69 is on the low side compared to the rest of the industry. TPST is outperformed by 80.36% of its industry peers.
TPST has a Quick Ratio of 1.69. This is a normal value and indicates that TPST is financially healthy and should not expect problems in meeting its short term obligations.
TPST has a Quick ratio of 1.69. This is in the lower half of the industry: TPST underperforms 79.10% of its industry peers.
Industry RankSector Rank
Current Ratio 1.69
Quick Ratio 1.69

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.64% over the past year.
EPS 1Y (TTM)28.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.30% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.09%
EPS Next 2Y20.68%
EPS Next 3Y9.95%
EPS Next 5Y8.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TPST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TPST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.68%
EPS Next 3Y9.95%

More info and screens

0

5. Dividend

5.1 Amount

TPST does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TEMPEST THERAPEUTICS INC

NASDAQ:TPST (1/6/2025, 7:21:58 PM)

After market: 0.9599 +0.01 (+1.13%)

0.9492

0 (-0.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners22.43%
Inst Owner Change0%
Ins Owners0.24%
Ins Owner Change-196.29%
Market Cap41.42M
Analysts86.67
Price Target18.36 (1834.26%)
Short Float %7.4%
Short Ratio1.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-6.61%
Min EPS beat(2)-11.04%
Max EPS beat(2)-2.17%
EPS beat(4)2
Avg EPS beat(4)-1.02%
Min EPS beat(4)-11.04%
Max EPS beat(4)5.68%
EPS beat(8)5
Avg EPS beat(8)5.76%
EPS beat(12)8
Avg EPS beat(12)7.41%
EPS beat(16)8
Avg EPS beat(16)-44.62%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.37%
EPS NY rev (1m)0%
EPS NY rev (3m)8.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.62
P/tB 3.62
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)-1.06
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -104.97%
ROE -310.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.76%
ROA(5y)-63.32%
ROE(3y)-128.62%
ROE(5y)-114.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 104.99%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.69
Quick Ratio 1.69
Altman-Z -10.02
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)56.65%
Cap/Depr(5y)117.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.58%
EPS Next Y27.09%
EPS Next 2Y20.68%
EPS Next 3Y9.95%
EPS Next 5Y8.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-24.35%
EBIT Next 3Y-23.33%
EBIT Next 5Y-21.71%
FCF growth 1Y10.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.82%
OCF growth 3YN/A
OCF growth 5YN/A